메뉴 건너뛰기
The Lancet
Volumn 379, Issue 9827, 2012, Pages 1680-1682
Personalised antiplatelet treatment: A RAPIDly moving target
Author keywords

[No Author keywords available]
Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; PRASUGREL;
EID: 84860538182     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)60431-0     Document Type: Note
Times cited : (10)
References (7)
  • 1
    • 84860538806 scopus 로고    scopus 로고
    • Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): A prospective, randomised, proof-of-concept trial
    • published online March 29. DOI:10.1016/S0140-6736 12 60161-5
    • Roberts JD, Wells GA, Le May MR, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 2012; published online March 29. DOI:10.1016/S0140-6736 (12) 60161-5.
    • (2012) Lancet
    • Roberts, J.D.1    Wells, G.A.2    Le May, M.R.3
  • 2
    • 80052573217 scopus 로고    scopus 로고
    • Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: A time-dependent analysis of the Gauging Responsiveness with a Verify Now P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial
    • Price MJ, Angiolillo DJ, Teirstein PS, et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a Verify Now P2Y12 assay: impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 2011;124:1132-37.
    • (2011) Circulation , vol.124 , pp. 1132-1137
    • Price, M.J.1    Angiolillo, D.J.2    Teirstein, P.S.3
  • 3
    • 79952598836 scopus 로고    scopus 로고
    • Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial
    • Price MJ, Berger PB, Teirstein PS, et al. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097-105.
    • (2011) JAMA , vol.305 , pp. 1097-1105
    • Price, M.J.1    Berger, P.B.2    Teirstein, P.S.3
  • 4
    • 78049326068 scopus 로고    scopus 로고
    • Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: A meta-analysis
    • Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010;304:1821-30.
    • (2010) JAMA , vol.304 , pp. 1821-1830
    • Mega, J.L.1    Simon, T.2    Collet, J.P.3
  • 6
    • 79960613122 scopus 로고    scopus 로고
    • Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy
    • Scott SA, Sangkuhl K, Gardner EE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 2011;90:328-32.
    • (2011) Clin Pharmacol Ther , vol.90 , pp. 328-332
    • Scott, S.A.1    Sangkuhl, K.2    Gardner, E.E.3
  • 7
    • 84555195438 scopus 로고    scopus 로고
    • CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: A systematic review and meta-analysis
    • Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 2011;306:2704-14.
    • (2011) JAMA , vol.306 , pp. 2704-2714
    • Holmes, M.V.1    Perel, P.2    Shah, T.3    Hingorani, A.D.4    Casas, J.P.5

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.